Hydrochlorothiazide (+) Losartan Potassium vs. Amlodipine Comparative Study (0954A-314)

Organon and Co174 enrolled

Overview

An efficacy and safety study of hydrochlorothiazide (+) losartan potassium compared to amlodipine at week 12 in Korean patients with essential hypertension

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

174

Conditions

Essential Hypertension

Interventions

MK0954A; hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 12 weeksDRUG

Eligibility

Sex: ALLMin age: 20 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients of age 20 70 75 with essential hypertension * SiDBP 90 \~ 114mmHg at V1 \& V2 Exclusion Criteria: * Patient has known or suspected secondary hypertension * Patient has a history of malignant hypertension (SiSBP \> 210mmHg) * Individuals has a known sensitivity or intolerance to HCTZ or any AIIAs, or any sulfonamide-derived drugs. * Patient has shown significant abnormal laboratory evaluations

Outcomes

Primary Outcomes

Antihypertensive efficacy of 12 weeks of treatment with hydrochlorothiazide (+) losartan potassium/amlodipine

Secondary Outcomes

Safety/Tolerability

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.